V
COGT icon

Veritable’s Cogent Biosciences COGT Stock Holding History

Veritable’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,331
Closed -$205K – 162
2023
Q2 		$205K Buy
17,331
+110
+0.6% +$1.26K ﹤0.01% 837
2023
Q1 		$186K Hold
17,221
– – ﹤0.01% 854
2022
Q4 		$199K Hold
17,221
– – ﹤0.01% 824
2022
Q3 		$257K Sell
17,221
-15
-0.1% -$206 0.01% 675
2022
Q2 		$155K Sell
17,236
-39,784
-70% -$272K ﹤0.01% 848
2022
Q1 		$427K Buy
57,020
+7,180
+14% +$50K 0.01% 606
2021
Q4 		$428K Hold
49,840
– – 0.01% 606
2021
Q3 		$419K Hold
49,840
– – 0.01% 601
2021
Q2 		$404K Buy
49,840
+39,799
+396% +$336K 0.01% 596
2021
Q1 		$88K Buy
+10,041
New +$96.7K ﹤0.01% 825

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Veritable's COGT Position: Q3 2023 in Review

Veritable sold out of Cogent Biosciences (COGT) in Q3 2023, closing a stake of 17,331 shares — an estimated $205K sold.

Veritable first reported a position in COGT in Q1 2021 and held it in 10 quarters. The position peaked at $428K in Q4 2021. 135 funds tracked by Wall St. Rank hold COGT as of Q3 2023.

  • Veritable reported no remaining Cogent Biosciences position as of Q3 2023 after selling out during the quarter.
  • Veritable sold 17,331 Cogent Biosciences shares in Q3 2023, an estimated $205K.
  • Veritable first reported a position in Cogent Biosciences in Q1 2021 and held it in 10 quarters.
  • Veritable's Cogent Biosciences position peaked at $428K in Q4 2021.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.